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Supplementary Figures 
 
 
 
 
Supplementary Figure 1:  Principal Components plot of genotypes of the AADM participants 
 
  
 
 
 
 
 
 
Supplementary Figure 2:  QQ plot for the discovery GWAS for T2D: the AADM Study 
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Supplementary Figure 3:  ZRANB3 expression in T2D target tissues. Figure generated from 
ENCODE data  
 
 
 
 
Supplementary Figure 4:  Manhattan plot of meta-analysis of African ancestry - AADM and 
African American - samples  
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Gene Mean RPKM SE RPKM Annotation of gene 
isl1 1.71522249 0.27058771 b-cell gene 
pdx1 0.98223831 0.01594826 b-cell gene 
ins 0.22035648 0.11522795 b-cell gene 
zranb3 0.1000469 0.0026255 Gene of interest 
mitfb 0.04878491 0.0102144 Skin transcription factor (TF) 
cmlc2 0 0 Heart marker by 48 hpf 
opg 0 0 Osteoclast differentiation TF 
 
Supplementary Figure 5: Expression of zranb3 and *selected genes in zebrafish b-cells isolated 
at 5 days post-fertilization (dpf) A: Expression of zranb3 by RNA-seq in 5dpf zebrafish. Selected 
genes include both known b-cell genes and genes unrelated to b-cells to give context to zranb3 
expression 
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*Relative expression of cmlc2 in mCherry- cells shown at far right for reference  
 
Average values relative to ACTIN 
Relative 
expression Std Dev 
Insulin 0.001995 0.00026163 
gck 0.000376 3.53553E-05 
zranb3 0.000167667 2.08407E-05 
cmlc2 0 0 
(cmlc2 in mCherry- cells) 0.00386 7.07107E-05 
 
Supplementary Figure 5b. zranb3 expression by qPCR in beta-cells isolated from 5dpf 
zebrafish* 
  
A 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6: (A) Validation of the efficacy of the zranb3 MO (5ng) to significantly 
suppress zranb3 mRNA expression without inducing off-target toxicity evaluated using the 
presence of a marker of MO-induced toxicity, the delta113 isoform of p53. (B) Wholemount 
bright field images of control MO and zranb3 MO-injected larvae shows no morphological 
developmental defects at 5 dpf 
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Supplementary Figure 7:  Glucose uptake as determined by retinal fluorescence after 2-NBDG 
treatment. (A) Quantification of glucose uptake at various concentrations in wild-type and 
zranb3 MO-injected larvae by quantification of 2-NBDG fluorescence. (B) Fluorescent 2-NBDG 
staining in control (left panel) and zranb3 MO-injected (right panel) larvae 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8: Cell cycle analysis of FACS-sorted b-cells control versus zranb3 MO-
injected embryos showing similar DNA histogram profiles (upper panels) for cells from control 
and zranb3 MO injected (MO-1, MO-2), quantified in lower panels.  
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Supplementary Figure 9: Gating strategy for cell cycle determination of zebrafish cells in 
Tubingen (top) and Tg(insa:mCherry) (bottom) animals. (A) Gating strategy for cells. (B) Gating 
strategy for single cells. (C) Gating strategy for mCherry+ (β) and mCherry- (non-β) cells. (D) 
Gating strategy for G1, S, and G2/M phases of the cell cycle. 
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Supplementary Tables 
 
 
 
Supplementary Table 1: Characteristics of discovery study sample in the AADM Study 
Characteristic T2D Controls 
N 2,342 2,889 
Gender (% Female) 58.5 67.4 
Age (years) 55.4 (11.0) 45.7 (12.9) 
BMI (kg/m2) 26.8 (5.4) 26.5 (6.0) 
Waist circumference (cm) 93.7 (11.5) 88.5 (13.2) 
Fasting blood glucose (mg/dl)* 153 (109, 232) 85 (79,92) 
 
*Median (interquartile range); all other figures are mean (SD) 
 
  
 
Supplementary Table 2: eQTL* annotation of ZRANB3 genome wide significant SNPs in the AADM Study 
 
 Haplotype block** Flanking SNPs 
Index SNP hg19 
coordinates 
(size) 
Number 
of target 
genes 
for 
which 
eQTLs 
Is in 
cis/trans 
eQTL for T2D-
related genes 
in GWAS 
Catalog 
SNP ID Is cis-
eQTL 
for 
ZRANB3 
Is trans-
eQTL 
(genes) 
eQTL 
for 
T2D-
related 
genes 
in 
GWAS 
Catalog 
2:136064024 2:136046052-
136064758 
(18.7 kb) 
5/43 MCM6 
DARS 
IL23R/IL12RB2 
SLC44A4 
ZFAT 
rs57510176  
 
 
Yes Yes 
ATXN10 
- 
    rs72982351 Yes No - 
rs1465146591 2:136016079-
136032905 
(16.8 kb) 
5/35 MCM6 
DARS 
DGKB 
GTF3AP5-
AGMO 
IL23R/IL12RB2 
SLC44A4 
rs141414859 Yes Yes 
DGKB, 
CGREF1 
DGKB 
    rs112334908 Yes No  
 
*eQTL data from the Framingham Heart Study (FHS) eQTL database11 accessed through the NCBI 
Molecular QTL Browser  
**Haplotype block around index SNP defined using 1000 Genomes Phase 3 AFR data 
  
 
Supplementary Table 3: Local replication of established T2D loci in the AADM Study 
 
Chr Pos Locus Population Index SNP r2 Best SNP MAF BETA SE PVAL df Adj. P 
1 40046093 MACF1 European rs3768321 0.5641 rs111768751 0.0138 0.536 0.2008 7.59E-03 4.19 3.19E-02 
1 154320191 ATP8B2 Japanese rs67156297 0.3723 1:154320191 0.0135 0.6282 0.208 2.53E-03 8.49 2.14E-02 
2 43524295 THADA European rs6757251 0.6421 rs534246205 0.2919 -0.1422 0.0512 5.46E-03 8.45 4.62E-02 
2 57413142 CCDC85A Japanese rs1116357 0.3308 rs56137178 0.2368 0.1727 0.0545 1.54E-03 6.92 1.07E-02 
2 161339964 RBMS1 non-
European 
rs1563575 0.3083 rs62175963 0.2465 0.1669 0.0543 2.11E-03 6.09 1.28E-02 
4 185721370 ACSL1  Novel 
1000G 
signal 
rs60780116 0.475 rs11936062 0.6677 -0.1493 0.0488 2.24E-03 19.37 4.33E-02 
6 32523888 HLA-DQA1  Novel 
1000G 
signal 
rs9271774 0.3458 rs66553215 0.6361 0.1939 0.0545 3.73E-04 7.8 2.92E-03 
6 126657472 CENPW European rs11759026 0.3055 rs4897175 0.3383 0.1634 0.0497 1.01E-03 2.24 2.26E-03 
9 22289853 DMRTA1 Japanese rs1575972 0.9343 rs12000501 0.3117 -0.2159 0.0494 1.22E-05 13.85 1.69E-04 
9 84380739 TLE1 European rs9410573 0.3095 rs7033983 0.9656 0.4575 0.1423 1.31E-03 27.03 3.53E-02 
10 12246105 CDC123/ 
CAMK1D 
European rs11257659 0.5412 rs1320195 0.3439 0.1687 0.0497 6.79E-04 25.76 1.75E-02 
10 94281685 HHEX/IDE European rs11187140 0.6385 rs10882074 0.0468 -0.399 0.1136 4.46E-04 9.12 4.07E-03 
11 2193597 MIR4686 Japanese rs7107784 0.539 rs10770140 0.456 -0.1793 0.0473 1.48E-04 17.18 2.54E-03 
11 17418477 KCNJ11 European rs5219 0.9123 rs757110 0.9168 -0.2223 0.0621 3.46E-04 10.46 3.62E-03 
13 80765272 SPRY2 European rs11616380 0.3617 rs2876754 0.5826 0.1779 0.0503 4.06E-04 15.56 6.32E-03 
18 57766512 MC4R other rs1942880 0.7766 rs1539952 0.2322 0.1586 0.0531 2.85E-03 9.78 2.79E-02 
  
 
Supplementary Table 4: Top hits from meta-analysis of African ancestry – AADM and five-
cohort African American - studies 
 
 
SNP GENE Weighted 
N 
Z score P-value Direction Comments 
rs386418874 TCF7L2 13830 6.536 6.33E-11 ++ Known T2D locus 
rs4532315 Intergenic 13830 -5.734 9.80E-09 -- No known association 
with any phenotype;  
rs4072825 TH-INS 13830 5.584 2.35E-08 ++ Reported T2D GWAS 
locus1; in the IGF-INS-
TH region associated 
with T2D and metabolic 
phenotypes; associated 
with MODY and 
transient neonatal 
diabetes; Mutations 
associated with Segawa 
syndrome (a 
neurological syndrome) 
rs111248619 KCNQ3 13830 5.559 2.71E-08 ++ Potassium voltage-
gated channel. 
Associated with 
neonatal epilepsy. Not 
previously known to be 
associated with T2D;  
 
 
 
  
Supplementary Notes 
 
Supplementary Note 1: ZRANB3 primers 
 
EF1alpha 
FWD - CTGGAGGCCAGCTCAAACAT 
REV - ATCAAGAAGAGTAGTACCGCTAGCATTAC 
 
RPIII 
FWD - TCTGGAGGACTGTAAGAGGTATGC 
REV - TCTGGAGGACTGTAAGAGGTATGC 
 
ACTIN 
FWD - CGAGCTGTCTTCCCATCCA 
REV - CGAGCTGTCTTCCCATCCA 
 
ZRANB3 
FWD - GAGACATCAACTTGGTGGAGAG 
REV - TTGTATCCGCGGAGGTTTG 
 
INS 
FWD - TGGTCGATGCCCTTTATCTGG 
REV - AGATGCTGCAGGGTTTGTGG 
 
GCK 
FWD - TGAAAGTGGGTGAGGATGAAG 
REV - CTGCATATCTGACTTCCTGGAC 
 
OPG/TNSF13B 
FWD - GGAAGAGCAGGGCACTATTT 
REV - GCCGACCACGTTCTTCTTTA 
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